Immunology and Biotherapies
20.7K views | +4 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
Scoop.it!

Cancer Immunology at Dana-Farber | Insight

Cancer Immunology at Dana-Farber | Insight | Immunology and Biotherapies | Scoop.it
The mission of the CVC is to translate the promising insights from basic immunology into therapeutics that benefit cancer patients. The CVC undertook a series of clinical trials exploring the biologic activity of autologous tumor ...
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in ANCA vasculitis

The effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in ANCA vasculitis | Immunology and Biotherapies | Scoop.it
To evaluate the effect of rituximab on pathogenic autoantibodies and total immunoglobulin levels, and to identify serious adverse events, in patients with ANCA vasculitis treated with continuous B cell depletion.We conducted a retrospective analysis of ...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Healthy competition intensifies 30-year quest for HIV vaccine

Healthy competition intensifies 30-year quest for HIV vaccine | Immunology and Biotherapies | Scoop.it
In 1984, after HIV was identified as the cause of AIDS, the US secretary of health, Margaret Heckler, declared a vaccine would be found within two years. Reports of a mysterious virus predominantly affecting gay men had been ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

T Cell Therapy Research: From Bench to Bedside

T Cell Therapy Research: From Bench to Bedside | Immunology and Biotherapies | Scoop.it
T Cell Isolation, Activation and Expansion Reagents for Cellular Therapy Research...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibito...

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibito... | Immunology and Biotherapies | Scoop.it
The present review is part of the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus
document on the safety of targeted and biological therapies.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation - Song - 2018 - European Journal of Immunology - Wiley Online ...

Adoptive transfer of donor NK cells has the potential of mediating graft‐versus‐leukemia (GVL) effect while suppressing acute graft‐versus‐host‐disease (aGVHD) during allogeneic hematopoietic stem cell transplantation (allo‐HSCT). However, these beneficial effects are limited by the transient function of adoptively transferred NK cells. Previous studies demonstrate that cytokine‐induced memory‐like NK cells that are preactivated by IL‐12, IL‐15, and IL‐18 have enhanced effector functions and long life span in vivo. Here, we investigated the effects of IL‐12/18‐preactivated and IL‐12/15/18‐preactivated donor NK cells on GVL and aGVHD in a murine model of allo‐HSCT. We found that both IL‐12/18‐ and IL‐12/15/18‐preactivated NK cells mediated stronger GVL effect than control NK cells mainly due to their elevated activation/cytotoxicity and sustained proliferative potential. Interestingly, we observed that although both IL‐12/18‐ and IL‐12/15/18‐preactivated NK cells significantly inhibited severe aGVHD, only the IL‐12/18‐preactivated NK cells maintained the beneficial effect of donor NK cells on mild aGVHD. The IL‐12/15/18‐preactivated NK cell infusion accelerated aGVHD in the fully‐mismatched mild aGVHD model. Our results demonstrated that IL‐12/18‐preactivated NK cells displayed sustained and enhanced GVL functions, and could mitigate aGVHD despite the severity of the disease. IL‐12/18‐preactivated donor NK cell infusion may be an effective and safe adoptive therapy after allo‐HSCT.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

First description of mEAK-7 gene could suggest path toward therapies for cancer, other diseases | UCLA

First description of mEAK-7 gene could suggest path toward therapies for cancer, other diseases | UCLA | Immunology and Biotherapies | Scoop.it
Researchers led by UCLA’s Dr. Paul Krebsbach are the first to characterize the mechanism of the gene, and they found it regulates the molecular process that ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Immune System's Antibodies Target Multiple Microbes

For the first time, scientists found that antibodies produced by the immune system can target multiple microbes, as opposed to just one type of microbe.Fr...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Decreased circulating T regulatory lymphocytes in obese patients undergoing bariatric surgery

Decreased circulating T regulatory lymphocytes in obese patients undergoing bariatric surgery | Immunology and Biotherapies | Scoop.it
Objective It has been previously demonstrated that T lymphocytes may be involved in the development of hypertension and microvascular remodeling, and that circulating T effector lymphocytes may be increased in hypertension.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Heme Oxygenase-1: A Metabolic Nike

Heme Oxygenase-1: A Metabolic Nike | Immunology and Biotherapies | Scoop.it
Significance: Heme degradation, which was described more than 30 years ago, is still very actively explored with many novel discoveries on its role in various disease models every year. Recent Advances: The heme oxygenases (HO) are metabolic enzymes that ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Spotlight Categories Latest Advances in CAR-T Cell Manufacture & Clinical Developments

Spotlight Categories Latest Advances in CAR-T Cell Manufacture & Clinical Developments | Immunology and Biotherapies | Scoop.it
Bringing you the latest cutting edge research and commentary in bioscience.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Pegylated Interferon-α–Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy–Treated HIV-1/Hepatitis C Virus–Coinfected Pati...

Pegylated Interferon-α–Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy–Treated HIV-1/Hepatitis C Virus–Coinfected Pati... | Immunology and Biotherapies | Scoop.it
In antiretroviral-treated HIV-1/hepatitis C virus–coinfected patients, IFN-α treatment decreases cell-associated HIV-1 DNA levels, changes the natural killer (N...
more...
No comment yet.
Suggested by Isabel Olazabal
Scoop.it!

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk

Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk | Immunology and Biotherapies | Scoop.it

Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies.

In this study, we identify galectin-1 (Gal1), a glycan-binding protein that is highly overexpressed in PDA stroma, as a major driver of pancreatic cancer progression. Genetic deletion of Gal1 in a mouse model of PDA results in a significant increase in survival through mechanisms involving decreased stroma activation, attenuated vascularization, and enhanced T cell infiltration leading to diminished metastasis rates.

In a human setting, in human pancreatic stellate cells (HPSCs), Gal1-driven pathways promote cancer proliferation, migration, and invasión. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression. Thus, Gal1 hierarchically regulates different events implicated in PDA biology including tumor cell proliferation, invasion, angiogenesis, inflammation, and metastasis, highlighting the broad therapeutic potential of Gal1-specific inhibitors, either alone or in combination with other therapeutic modalities.

Gilbert C FAURE's insight:

thanks, after one previous post

https://www.scoop.it/t/immunology-and-biotherapies?q=galectin

 and

some on another topic

https://www.scoop.it/t/immunology?q=galectin

 as well as more (120) through

https://www.scoop.it/search?q=galectin

 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data | Genome Medicine | Full Text

BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data | Genome Medicine | Full Text | Immunology and Biotherapies | Scoop.it
B cells play a critical role in the immune response by producing antibodies, which display remarkable diversity. Here we describe a bioinformatic pipeline, BALDR (BCR Assignment of Lineage using De novo Reconstruction) that accurately reconstructs the paired heavy and light chain immunoglobulin...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Antiviral T-Cells for Adenovirus in the Pre-Transplant Period: a Bridge Therapy for Severe Combined Immunodeficiency

Antiviral T-Cells for Adenovirus in the Pre-Transplant Period: a Bridge Therapy for Severe Combined Immunodeficiency | Immunology and Biotherapies | Scoop.it
• Virus specific T-cell therapy was safely utilized in a patient with severe combined immunodeficiency in the pre-transplant period without graft versus host disease.• VST infusion followed by transplant was associated with clearance of disseminated adenovirus.• VST infusion may be an effective...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma | Immunology and Biotherapies | Scoop.it
In a multicenter phase 1 study, Locke, Neelapu, et al. report tolerability and safety
of KTE-C19, a CD19 chimeric antigen receptor technology, in patients with chemorefractory
DLBCL. More importantly, KTE-C19 could provide durable clinical benefit in this difficult-to-treat patient population,...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes | Immunology and Biotherapies | Scoop.it
ABSTRACT
The four dengue virus serotypes (DENV1 to 4) cause dengue, a major public health problem worldwide. Individuals exposed to primary DENV infections develop serotype-specific neutralizing antibodies, including strongly neutralizing antibodies targeting quaternary epitopes. To date, no studies have measured the levels and kinetics of serum antibodies directed to such epitopes among populations in regions where dengue is endemic. Here, we use a recombinant DENV4 (rDENV4/3-M14) displaying a major DENV3 type-specific quaternary epitope recognized by human monoclonal antibody 5J7 to measure the proportion, magnitude, and kinetics of DENV3 type-specific neutralizing antibody responses targeting this epitope. Primary DENV3 sera from 30 individuals in a dengue hospital-based study in Nicaragua were studied 3, 6, 12, and 18 months post-infection, alongside samples collected annually 1 to 4 years post-primary DENV3 infection from 10 individuals in a cohort study in Nicaragua. We found substantial individual variation in the proportion of DENV3 type-specific neutralizing antibody titers attributed to the 5J7 epitope (range, 0 to 100%), with the mean significantly increasing from 22.6% to 41.4% from 3 to 18 months. We extended the transplanted DENV3 5J7 epitope on the virion (rDENV4/3-M16), resulting in increased recognition in several individuals, helping define the footprint of the epitope. However, 37% and 13% of the subjects still showed little to no recognition of the 5J7 epitope at 3 and 18 months, respectively, indicating that one or more additional DENV3 type-specific epitopes exist. Overall, this study demonstrates how DENV-immune plasma from populations from areas of endemicity, when coupled with structurally guided recombinant viruses, can help characterize the epitope-specific neutralizing antibody response in natural DENV infections, with direct implications for design and evaluation of dengue vaccines.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity: mAbs: Vol 0, No ja

Abstract
Therapeutic monoclonal antibodies are the fastest growing class of biological therapeutics for the treatment of various cancers and inflammatory disorders. In cancer immunotherapy, some IgG1 antibodies rely on the Fc-mediated immune effector function, antibody-dependent cellular cytotoxicity (ADCC), as the major mode of action to deplete tumor cells. It is well-known that this effector function is modulated by the N-linked glycosylation in the Fc region of the antibody. In particular, absence of core fucose on the Fc N-glycan has been shown to increase IgG1 Fc binding affinity to the FcγRIIIa present on immune effector cells such as natural killer cells and lead to enhanced ADCC activity. As such, various strategies have focused on producing afucosylated antibodies to improve therapeutic efficacy. This review discusses the relevance of antibody core fucosylation to ADCC, different strategies to produce afucosylated antibodies, and an update of afucosylated antibody drugs currently undergoing clinical trials as well as those that have been approved.

KEYWORDS: ADCC, Fc fucosylation, Fc gamma receptors, in vivo efficacy, therapeutic monoclonal antibodies
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Roadblocks and resolutions in eukaryotic translation

Roadblocks and resolutions in eukaryotic translation | Immunology and Biotherapies | Scoop.it
Ribosomes encounter obstacles during translation elongation that cause their stalling and can have a profound impact on protein yield. Ribosome stalling depends on the genetic code, amino acid availability, regulatory elements and mRNA context and can be resolved by resumption of translation or by...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

In cancer immunotherapies, a radioactive crystal ball may predict success

In cancer immunotherapies, a radioactive crystal ball may predict success | Immunology and Biotherapies | Scoop.it
If a new technique reported on Monday works as well in people as in lab mice, physicians will be able to predict who will and won't benefit from immune therapies for cancer.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations

Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations | Immunology and Biotherapies | Scoop.it
Article...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cutting Edge: Blockade of Inhibitor of Apoptosis Proteins Sensitizes Neutrophils to TNF- but Not Lipopolysaccharide-Mediated Cell Death and IL-1β Secretion

Cutting Edge: Blockade of Inhibitor of Apoptosis Proteins Sensitizes Neutrophils to TNF- but Not Lipopolysaccharide-Mediated Cell Death and IL-1β Secretion | Immunology and Biotherapies | Scoop.it
The mammalian inhibitor of apoptosis proteins (IAPs) are key regulators of cell death and inflammation. A major function of IAPs is to block the formation of a cell death–inducing complex, termed the ripoptosome, which can trigger caspase-8–dependent apoptosis or caspase-independent necroptosis.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. - PubMed - NCBI

Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Format: AbstractSend to Transplantation. 2018 Feb;102(2):193-208. doi: 10.1097/TP.0000000000002027. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. Clemente WT1,2, Pierrotti LC3, Abdala E4, Morris MI5, Azevedo LS6, López-Vélez R7, Cuenca-Estrella M8, Torre-Cisneros J9, Petersen E10, Camargo LFA11, Wright AJ12, Beeching NJ13,14, Vilela EG15, Santoro-Lopes G16,17, Len O18, Stucchi RSB19, Manuel O20, Faria LC21, Leblebicioglu H22, Huprikar S23, Molina I24, Mourão PHO25, Kotton CN26, Aguado JM27; working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation. Author information 1 Department of Laboratory Medicine - Medical School - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 2 Transplant Unit and Infection Control Commission. Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3 Infectious Diseases Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. 4 Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de São Paulo, Brazil. 5 Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL. 6 Kidney Transplantation Unit, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brazil. 7 National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramón y Cajal University Hospital, Madrid, Spain. 8 Spanish National Center for Microbiology, Instituto de Salud Carlos III, Madrid, Spain. 9 Department of Infectious Diseases. Maimonides Biomedical Research Institute of Cordoba (IMIBIC)-Reina Sofia University Hospital-University of Cordoba (UCO), Spain. 10 Department of Infectious Diseases, The Royal Hospital, Muscat, Oman. 11 Hospital Israelita Albert Einstein, São Paulo, Brazil. 12 Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, Boston, MA. 13 Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom. 14 NIHR Health Protection Research Unit (HPRU) in Gastrointestinal Infections, The Farr Institute, University of Liverpool, United Kingdom. 15 Alfa Institute of Gastroenterology, Clinic Hospital of Federal University of Minas Gerais, Belo Horizonte, Brazil. 16 Infectious Diseases Clinic, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil. 17 Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil. 18 Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 19 Unit of Liver Transplantation, Hospital de Clínicas, State University of Campinas (UNICAMP), São Paulo, Brazil. 20 Infectious Diseases Service and Transplantation Center, University Hospital (CHUV), University of Lausanne, Switzerland. 21 Department of Internal Medicine of Faculdade de Medicina da Universidade Federal de Minas Gerais. Gastroenterology Alfa Institute, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 22 Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University Medical School, Samsun, Turkey. 23 Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY USA. 24 Tropical Medicine and International Health Unit, Infectious Disease Department, Vall d'Hebron University Hospital. PROSICS Barcelona, Spain. 25 Hospital das Clínicas da Universidade Federal de Minas Gerais (HC/UFMG), Belo Horizonte, Brazil. 26 Infectious Diseases Division, Massachusetts General Hospital, Boston, MA. 27 Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain. Abstract The Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America clinical practice guideline is intended to guide clinicians caring for solid-organ transplant (SOT) donors, candidates and recipients regarding infectious diseases (ID) issues related to this geographical region, mostly located in the tropics. These recommendations are based on both systematic reviews of relevant literature and expert opinion from both transplant ID and travel medicine specialists. The guidelines provide recommendations for risk evaluation and laboratory investigation, as well as management and prevention of infection of the most relevant endemic diseases of Latin America. This summary includes a brief description of the guideline recommendations but does not include the complete rationale and references for each recommendation, which is available in the online version of the article, published in this journal as a supplement. The supplement contains 10 reviews referring to endemic or travel diseases (eg, tuberculosis, Chagas disease [ChD], leishmaniasis, malaria, strongyloidiasis and schistosomiasis, travelers diarrhea, arboviruses, endemic fungal infections, viral hepatitis, and vaccines) and an illustrative section with maps (http://www.pmourao.com/map/). Contributors included experts from 13 countries (Brazil, Canada, Chile, Denmark, France, Italy, Peru, Spain, Switzerland, Turkey, United Kingdom, United States, and Uruguay) representing four continents (Asia, the Americas and Europe), along with scientific and medical societies. PMID: 29381647 DOI: 10.1097/TP.0000000000002027 LinkOut - more resources Full Text Sources PubMed Commons home PubMed Commons 0 comments How to join PubMed Commons
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Immunoscore Validation - Society for Immunotherapy of Cancer (SITC)

Immunoscore Validation - Society for Immunotherapy of Cancer (SITC) | Immunology and Biotherapies | Scoop.it
To introduce immune parameters into tumor classification systems, SITC initaited and brokered the Immunoscore Validation Project - a global study correlating tumor immune infiltration with clinical outcomes in more than 3,000 cancer patients with state I-III colon cancer.

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1–Infected Individuals

Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1–Infected Individuals | Immunology and Biotherapies | Scoop.it
HIV-1 infection is associated with B cell dysregulation and dysfunction. In HIV-1–infected patients, we previously reported preservation of intestinal lymphoid structures and dendritic cell maturation pathways after early combination antiretroviral therapy (e-ART), started during the acute phase...
more...
No comment yet.